Frank Mauler

1.1k total citations
18 papers, 929 citations indexed

About

Frank Mauler is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, Frank Mauler has authored 18 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cellular and Molecular Neuroscience, 8 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in Frank Mauler's work include Neuroscience and Neuropharmacology Research (10 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Cannabis and Cannabinoid Research (5 papers). Frank Mauler is often cited by papers focused on Neuroscience and Neuropharmacology Research (10 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Cannabis and Cannabinoid Research (5 papers). Frank Mauler collaborates with scholars based in Germany, France and United States. Frank Mauler's co-authors include Ervin Horváth, Jean De Vry, Klaus Urbahns, Heiko A. Hofmann, Joachim Mittendorf, Volker Hinz, Thomas Fahrig, R. Jork, Angela Siegling and Johannes-Peter Stasch and has published in prestigious journals such as Brain Research, Journal of Pharmacology and Experimental Therapeutics and British Journal of Pharmacology.

In The Last Decade

Frank Mauler

18 papers receiving 904 citations

Peers

Countries citing papers authored by Frank Mauler

Since Specialization

Citations

This map shows the geographic impact of Frank Mauler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Mauler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Mauler more than expected).

Fields of papers citing papers by Frank Mauler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Mauler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Mauler. The network helps show where Frank Mauler may publish in the future.

Co-authorship network of co-authors of Frank Mauler

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Mauler. A scholar is included among the top collaborators of Frank Mauler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Mauler. Frank Mauler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Pharmacokinetics of repinotan in healthy and brain injured animals 2005 ·Biopharmaceutics & Drug Disposition ·Thomas Schwarz, Bernhard Beckermann, (unknown), Frank Mauler, Joachim Schuhmacher, D. Seidel, Wolfram Steinke, (unknown), (unknown)	4
2	Neuroprotective Efficacy of Repinotan HCl, a 5-HT_1A Receptor Agonist, in Animal Models of Stroke and Traumatic Brain Injury 2005 ·Journal of Cerebral Blood Flow & Metabolism ·Frank Mauler, Ervin Horváth	36
3	3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Jean De Vry, (unknown), (unknown), (unknown), (unknown), Heinrich Meier, Frank Mauler	49
4	Selective intermediate‐/small‐conductance calcium‐activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma 2004 ·European Journal of Neuroscience ·Frank Mauler, Volker Hinz, Ervin Horváth, Joachim Schuhmacher, Heiko A. Hofmann, (unknown), Michael G. Hahn, Klaus Urbahns	62
5	IKCa-channel blockers. Part 2: Discovery of cyclohexadienes 2004 ·Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Siegfried Goldmann, Jochen Krüger, Ervin Horváth, Joachim Schuhmacher, Rolf Grosser, Volker Hinz, Frank Mauler	20
6	BAY 38–7271: A Novel Highly Selective and Highly Potent Cannabinoid Receptor Agonist for the Treatment of Traumatic Brain Injury 2003 ·CNS Drug Reviews ·Frank Mauler, Ervin Horváth, Jean De Vry, (unknown), Thomas Schwarz, Steffen Sandmann, (unknown), Roland Heinig, (unknown)	27
7	4-Phenyl-4H-pyrans as IKCa channel blockers 2003 ·Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Ervin Horváth, Johannes-Peter Stasch, Frank Mauler	60
8	Activities of Prenylphenol Derivatives from Fruitbodies of Albatrellus spp. on the Human and Rat Vanilloid Receptor 1 (VR1) and Characterisation of the Novel Natural Product, Confluentin 2003 ·Archiv der Pharmazie ·Veronika Hellwig, (unknown), Frank Mauler, Joachim Freitag, Ji‐Kai Liu, (unknown), Marc Stadler	54
9	Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271 2003 ·Brain Research ·Frank Mauler, Volker Hinz, (unknown), (unknown), Ervin Horváth	46
10	4‐Phenyl‐4H‐pyrans as IK_Ca Channel Blockers. 2003 ·ChemInform ·Klaus Urbahns, Ervin Horváth, Johannes‐Peter Stasch, Frank Mauler	2
11	Characterization of the Diarylether Sulfonylester (−)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a Potent Cannabinoid Receptor Agonist with Neuroprotective Properties 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Frank Mauler, Joachim Mittendorf, Ervin Horváth, Jean De Vry	83
12	Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY x 3702 in vitro and in vivo 2001 ·Brain Research ·Frank Mauler, Thomas Fahrig, Ervin Horváth, R. Jork	72
13	Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain 2001 ·European Journal of Pharmacology ·Angela Siegling, Heiko A. Hofmann, (unknown), Frank Mauler, Jean De Vry	88
14	BAY36-7620: A Potent Non-Competitive mGlu1 Receptor Antagonist with Inverse Agonist Activity. 2001 ·Molecular Pharmacology ·Fiona Y. Carroll, Andreas Stolle, Philip M. Beart, A. Voerste, Isabelle Brabet, Frank Mauler, Cécile Joly, Horst Antonicek, Joël Bockaert, Thomas Müller, Jean‐Philippe Pin, Laurent Prézeau	12
15	BAY36-7620: A Potent Non-Competitive mGlu1 Receptor Antagonist with Inverse Agonist Activity. 2001 ·Molecular Pharmacology ·Fiona Y. Carroll, Andreas Stolle, Philip M. Beart, A. Voerste, Isabelle Brabet, Frank Mauler, Cécile Joly, Horst Antonicek, Joël Bockaert, Thomas Müller, Jean‐Philippe Pin, Laurent Prézeau	138
16	Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist 1998 ·Journal of Pharmacology and Experimental Therapeutics ·Jean De Vry, (unknown), Hans G. Heine, Joachim M. Greuel, Frank Mauler, Bernard Schmidt, (unknown), Thomas Gläser	52
17	Central and peripheral actions of the novel κ‐opioid receptor agonist, EMD 60400 1994 ·British Journal of Pharmacology ·Andrew Barber, Gerd D. Bartoszyk, Hartmut E. Greiner, Frank Mauler, Robert Murray, Christoph A. Seyfried, (unknown), Rudolf Gottschlich, J. Harting, (unknown)	15
18	A pharmacological profile of the novel, peripherally‐selectivek‐opioid receptor agonist, EMD 61753 1994 ·British Journal of Pharmacology ·Andrew Barber, Gerd D. Bartoszyk, (unknown), Rudolf Gottschlich, Hartmut E. Greiner, J. Harting, Frank Mauler, Klaus-Otto Minck, Robert Murray, (unknown), Christoph A. Seyfried	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact